{"id":"eyp-1901","safety":{"commonSideEffects":[{"rate":null,"effect":"Elevated intraocular pressure"},{"rate":null,"effect":"Cataract formation"},{"rate":null,"effect":"Implant-related complications"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"EYP-1901 is a refillable intracameral implant that provides long-term delivery of a corticosteroid to treat inflammatory eye conditions. The implant is placed in the anterior chamber of the eye and can be refilled to maintain therapeutic drug levels, reducing the need for frequent topical eye drops and improving patient compliance.","oneSentence":"EYP-1901 is a sustained-release corticosteroid implant designed to deliver anti-inflammatory therapy directly to the eye.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:06.599Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease"},{"name":"Anterior uveitis"}]},"trialDetails":[{"nctId":"NCT07449936","phase":"PHASE3","title":"COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME","status":"RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2026-02-26","conditions":"Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)","enrollment":240},{"nctId":"NCT07449923","phase":"PHASE3","title":"CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME","status":"RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2026-02-09","conditions":"Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)","enrollment":240},{"nctId":"NCT06668064","phase":"PHASE3","title":"A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56","status":"ACTIVE_NOT_RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2024-10-22","conditions":"Wet Age Related Macular Degeneration, wAMD","enrollment":400},{"nctId":"NCT06683742","phase":"PHASE3","title":"A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56","status":"ACTIVE_NOT_RECRUITING","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2024-11-27","conditions":"Wet Age Related Macular Degeneration, wAMD","enrollment":400},{"nctId":"NCT05381948","phase":"PHASE2","title":"Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)","status":"COMPLETED","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2022-06-30","conditions":"Wet Age-related Macular Degeneration","enrollment":161},{"nctId":"NCT05383209","phase":"PHASE2","title":"Study of EYP-1901 in Patients With Nonproliferative Diabetic Retinopathy (NPDR)","status":"COMPLETED","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2022-09-28","conditions":"Nonproliferative Diabetic Retinopathy","enrollment":77},{"nctId":"NCT06099184","phase":"PHASE2","title":"Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2024-01-15","conditions":"Diabetic Macular Edema","enrollment":27},{"nctId":"NCT04747197","phase":"PHASE1","title":"First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)","status":"COMPLETED","sponsor":"EyePoint Pharmaceuticals, Inc.","startDate":"2021-01-20","conditions":"Wet Age-related Macular Degeneration","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vorolanib"],"phase":"phase_3","status":"active","brandName":"EYP-1901","genericName":"EYP-1901","companyName":"EyePoint Pharmaceuticals, Inc.","companyId":"eyepoint-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EYP-1901 is a sustained-release corticosteroid implant designed to deliver anti-inflammatory therapy directly to the eye. Used for Dry eye disease, Anterior uveitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}